Caracemide is an agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase. In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. References: Egan JA, Filer CN. Tritiation and characterization of several suicide substrate enzyme inactivators. Appl Radiat Isot. 2014 Dec;94:302-5. doi: 10.1016/j.apradiso.2014.08.022. Epub 2014 Sep 16. PubMed PMID: 25305521.

纯度：≥98%

CAS：81424-67-1